Imaging neuroinflammation in multiple sclerosis using TSPO-PET

Clinical and Translational Imaging

Volumn 3, Issue 6, 2015, Pages 461-473

  Airas, Laura ^a   Rissanen, Eero ^a   Rinne, Juha O ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Imaging; Microglia; Multiple sclerosis; Progressive disease

Indexed keywords

18 KDA TRANSLOCATOR PROTEIN; ADENOSINE A2A RECEPTOR; BENZODIAZEPINE RECEPTOR; CANNABINOID 2 RECEPTOR; CYCLOOXYGENASE 2; DIAZEPAM; HISTAMINE H4 RECEPTOR; ISOQUINOLINE; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE C 11; RADIOLIGAND; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANTIGEN PRESENTING CELL; BINDING AFFINITY; BLOOD BRAIN BARRIER; BRAIN ISCHEMIA; CELL ACTIVATION; CELL INFILTRATION; CORRELATION COEFFICIENT; DISEASE SEVERITY; EXPANDED DISABILITY STATUS SCALE; FOLLOW UP; HUMAN; HUNTINGTON CHOREA; IMAGE ANALYSIS; IMMUNOMODULATION; MICROGLIA; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NERVE FIBER DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SIGNAL NOISE RATIO; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84952991286     PISSN: 22815872     EISSN: 22817565     Source Type: Journal    
DOI: 10.1007/s40336-015-0147-6     Document Type: Review

References (99)

1. Compston A, Coles A (2008) Multiple sclerosis. Lancet 372:1502–1517. doi:10.1016/S0140-6736(08)61620-7
2. Costello K, Halper J, Kalb R, Skutnik S, Rapp R (2014) The use of disease-modifying therapies in multiple sclerosis. Principles and current evidence. A consensus paper by the multiple sclerosis coalition. http://www.nationalmssociety.org/getmedia/5ca284d3-fc7c-4ba5-b005-ab537d495c3c/DMT_Consensus_MS_Coalition_color
3. Kutzelnigg A, Lassmann H (2014) Pathology of multiple sclerosis and related inflammatory demyelinating diseases. Handb Clin Neurol 122:15–58. doi:10.1016/B978-0-444-52001-2.00002-9
4. Kobelt G, Berg J, Lindgren P, Fredrikson S, Jonsson B (2006) Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry 77:918–926. doi:10.1136/jnnp.2006.090365
5. Lassmann H, van Horssen J, Mahad D (2012) Progressive multiple sclerosis: pathology and pathogenesis. Nat Rev Neurol 8:647–656. doi:10.1038/nrneurol.2012.168
6. Frischer JM, Bramow S, Dal-Bianco A et al (2009) The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 132:1175–1189. doi:10.1093/brain/awp070
7. Trapp BD, Nave KA (2008) Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci 31:247–269. doi:10.1146/annurev.neuro.30.051606.094313
8. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L (1998) Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338:278–285. doi:10.1056/NEJM199801293380502
9. Ching AS, Kuhnast B, Damont A, Roeda D, Tavitian B, Dolle F (2012) Current paradigm of the 18-kDa translocator protein (TSPO) as a molecular target for PET imaging in neuroinflammation and neurodegenerative diseases. Insights Imaging 3:111–119. doi:10.1007/s13244-011-0128-x
10. Biber K, Owens T, Boddeke E (2014) What is microglia neurotoxicity (Not)? Glia 62:841–854. doi:10.1002/glia.22654
11. Minghetti L, Levi G (1998) Microglia as effector cells in brain damage and repair: focus on prostanoids and nitric oxide. Prog Neurobiol 54:99–125
12. Gao Z, Tsirka SE (2011) Animal models of MS reveal multiple roles of microglia in disease pathogenesis. Neurol Res Int 2011:383087. doi:10.1155/2011/383087
13. McMahon EJ, Bailey SL, Castenada CV, Waldner H, Miller SD (2005) Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis. Nat Med 11:335–339. doi:10.1038/nm1202
14. Breij EC, Brink BP, Veerhuis R et al (2008) Homogeneity of active demyelinating lesions in established multiple sclerosis. Ann Neurol 63:16–25. doi:10.1002/ana.21311
15. Magliozzi R, Howell OW, Reeves C et al (2010) A gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Ann Neurol 68:477–493. doi:10.1002/ana.22230
16. Kutzelnigg A, Lucchinetti CF, Stadelmann C et al (2005) Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 128:2705–2712. doi:10.1093/brain/awh641
17. Howell OW, Rundle JL, Garg A, Komada M, Brophy PJ, Reynolds R (2010) Activated microglia mediate axoglial disruption that contributes to axonal injury in multiple sclerosis. J Neuropathol Exp Neurol 69:1017–1033. doi:10.1097/NEN.0b013e3181f3a5b1
18. Gao HM, Hong JS (2008) Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Trends Immunol 29:357–365. doi:10.1016/j.it.2008.05.002
19. Papadopoulos V, Baraldi M, Guilarte TR et al (2006) Translocator protein (18 kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol Sci 27:402–409. doi:10.1016/j.tips.2006.06.005
20. Casellas P, Galiegue S, Basile AS (2002) Peripheral benzodiazepine receptors and mitochondrial function. Neurochem Int 40:475–486
21. Doble A, Malgouris C, Daniel M et al (1987) Labelling of peripheral-type benzodiazepine binding sites in human brain with [3H]PK 11195: anatomical and subcellular distribution. Brain Res Bull 18:49–61
22. Schoemaker H, Morelli M, Deshmukh P, Yamamura HI (1982) [3H]Ro5-4864 benzodiazepine binding in the kainate lesioned striatum and Huntington’s diseased basal ganglia. Brain Res 248:396–401
23. Stephenson DT, Schober DA, Smalstig EB, Mincy RE, Gehlert DR, Clemens JA (1995) Peripheral benzodiazepine receptors are colocalized with activated microglia following transient global forebrain ischemia in the rat. J Neurosci 15:5263–5274
24. Vowinckel E, Reutens D, Becher B, Verge G, Evans A, Owens T, Antel JP (1997) PK11195 binding to the peripheral benzodiazepine receptor as a marker of microglia activation in multiple sclerosis and experimental autoimmune encephalomyelitis. J Neurosci Res 50:345–353. doi:10.1002/(SICI)1097-4547(19971015)50:2<345:AID-JNR22>3.0.CO;2-5
25. McGeer PL, Itagaki S, Boyes BE, McGeer EG (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology 38:1285–1291
26. Gerhard A, Pavese N, Hotton G et al (2006) In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson’s disease. Neurobiol Dis 21:404–412. doi:10.1016/j.nbd.2005.08.002
27. Ouchi Y, Yoshikawa E, Sekine Y, Futatsubashi M, Kanno T, Ogusu T, Torizuka T (2005) Microglial activation and dopamine terminal loss in early Parkinson’s disease. Ann Neurol 57:168–175. doi:10.1002/ana.20338
28. Cagnin A, Brooks DJ, Kennedy AM et al (2001) In-vivo measurement of activated microglia in dementia. Lancet 358:461–467. doi:10.1016/S0140-6736(01)05625-2
29. Edison P, Archer HA, Gerhard A et al (2008) Microglia, amyloid, and cognition in Alzheimer’s disease: an [11C](R)PK11195-PET and [11C]PIB-PET study. Neurobiol Dis 32:412–419. doi:10.1016/j.nbd.2008.08.001
30. Broaddus WC, Bennett JP Jr (1990) Peripheral-type benzodiazepine receptors in human glioblastomas: pharmacologic characterization and photoaffinity labeling of ligand recognition site. Brain Res 518:199–208
31. Vlodavsky E, Soustiel JF (2007) Immunohistochemical expression of peripheral benzodiazepine receptors in human astrocytomas and its correlation with grade of malignancy, proliferation, apoptosis and survival. J Neurooncol 81:1–7. doi:10.1007/s11060-006-9199-9
32. Su Z, Roncaroli F, Durrenberger PF et al (2015) The 18-kDa mitochondrial translocator protein in human gliomas: a 11C-(R)PK11195 PET imaging and neuropathology study. J Nucl Med. doi:10.2967/jnumed.114.151621
33. Banati RB, Myers R, Kreutzberg GW (1997) PK (‘peripheral benzodiazepine’)-binding sites in the CNS indicate early and discrete brain lesions: microautoradiographic detection of [3H]PK11195 binding to activated microglia. J Neurocytol 26:77–82
34. Banati RB, Newcombe J, Gunn RN et al (2000) The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain 123(Pt 11):2321–2337
35. Cosenza-Nashat M, Zhao ML, Suh HS, Morgan J, Natividad R, Morgello S, Lee SC (2009) Expression of the translocator protein of 18 kDa by microglia, macrophages and astrocytes based on immunohistochemical localization in abnormal human brain. Neuropathol Appl Neurobiol 35:306–328. doi:10.1111/j.1365-2990.2008.01006.x
36. Maeda J, Higuchi M, Inaji M et al (2007) Phase-dependent roles of reactive microglia and astrocytes in nervous system injury as delineated by imaging of peripheral benzodiazepine receptor. Brain Res 1157:100–111. doi:10.1016/j.brainres.2007.04.054
37. Junck L, Olson JM, Ciliax BJ et al (1989) PET imaging of human gliomas with ligands for the peripheral benzodiazepine binding site. Ann Neurol 26:752–758. doi:10.1002/ana.410260611
38. Banati RB, Goerres GW, Myers R et al (1999) [11C](R)-PK11195 positron emission tomography imaging of activated microglia in vivo in Rasmussen’s encephalitis. Neurology 53:2199–2203
39. Schweitzer PJ, Fallon BA, Mann JJ, Kumar JS (2010) PET tracers for the peripheral benzodiazepine receptor and uses thereof. Drug Discov Today 15:933–942. doi:10.1016/j.drudis.2010.08.012
40. Banati RB, Middleton RJ, Chan R et al (2014) Positron emission tomography and functional characterization of a complete PBR/TSPO knockout. Nat Commun 5:5452. doi:10.1038/ncomms6452
41. Kuhlmann AC, Guilarte TR (2000) Cellular and subcellular localization of peripheral benzodiazepine receptors after trimethyltin neurotoxicity. J Neurochem 74:1694–1704
42. Ji B, Maeda J, Sawada M et al (2008) Imaging of peripheral benzodiazepine receptor expression as biomarkers of detrimental versus beneficial glial responses in mouse models of Alzheimer’s and other CNS pathologies. J Neurosci 28:12255–12267. doi:10.1523/JNEUROSCI.2312-08.2008
43. Rojas S, Martin A, Arranz MJ et al (2007) Imaging brain inflammation with [(11)C]PK11195 by PET and induction of the peripheral-type benzodiazepine receptor after transient focal ischemia in rats. J Cereb Blood Flow Metab 27:1975–1986. doi:10.1038/sj.jcbfm.9600500
44. Tomasi G, Edison P, Bertoldo A et al (2008) Novel reference region model reveals increased microglial and reduced vascular binding of 11C-(R)-PK11195 in patients with Alzheimer’s disease. J Nucl Med 49:1249–1256. doi:10.2967/jnumed.108.050583
45. Turkheimer FE, Edison P, Pavese N et al (2007) Reference and target region modeling of [11C]-(R)-PK11195 brain studies. J Nucl Med 48:158–167
46. Yaqub M, van Berckel BN, Schuitemaker A et al (2012) Optimization of supervised cluster analysis for extracting reference tissue input curves in (R)-[(11)C]PK11195 brain PET studies. J Cereb Blood Flow Metab 32:1600–1608. doi:10.1038/jcbfm.2012.59
47. Giannetti P, Politis M, Su P et al (2014) Microglia activation in multiple sclerosis black holes predicts outcome in progressive patients: an in vivo [(11)C](R)-PK11195-PET pilot study. Neurobiol Dis 65:203–210. doi:10.1016/j.nbd.2014.01.018
48. Politis M, Giannetti P, Su P et al (2012) Increased PK11195 PET binding in the cortex of patients with MS correlates with disability. Neurology 79:523–530. doi:10.1212/WNL.0b013e3182635645
49. Rissanen E, Tuisku J, Rokka J, Paavilainen T, Parkkola R, Rinne JO, Airas L (2014) In vivo detection of diffuse inflammation in secondary progressive multiple sclerosis using PET imaging and the radioligand 11C-PK11195. J Nucl Med 55:939–944. doi:10.2967/jnumed.113.131698
50. Owen DR, Gunn RN, Rabiner EA et al (2011) Mixed-affinity binding in humans with 18-kDa translocator protein ligands. J Nucl Med 52:24–32. doi:10.2967/jnumed.110.079459
51. Owen DR, Yeo AJ, Gunn RN et al (2012) An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. J Cereb Blood Flow Metab 32:1–5. doi:10.1038/jcbfm.2011.147
52. International HapMap Project. refSNP rs6971 with alleles C/T in dbSNP b126
53. Kreisl WC, Jenko KJ, Hines CS et al (2013) A genetic polymorphism for translocator protein 18 kDa affects both in vitro and in vivo radioligand binding in human brain to this putative biomarker of neuroinflammation. J Cereb Blood Flow Metab 33:53–58. doi:10.1038/jcbfm.2012.131
54. Guo Q, Owen DR, Rabiner EA, Turkheimer FE, Gunn RN (2012) Identifying improved TSPO PET imaging probes through biomathematics: the impact of multiple TSPO binding sites in vivo. Neuroimage 60:902–910. doi:10.1016/j.neuroimage.2011.12.078
55. Lavisse S, Guillermier M, Herard AS et al (2012) Reactive astrocytes overexpress TSPO and are detected by TSPO positron emission tomography imaging. J Neurosci 32:10809–10818. doi:10.1523/JNEUROSCI.1487-12.2012
56. Dickens AM, Vainio S, Marjamaki P et al (2014) Detection of microglial activation in an acute model of neuroinflammation using PET and radiotracers 11C-(R)-PK11195 and 18F-GE-180. J Nucl Med 55:466–472. doi:10.2967/jnumed.113.125625
57. Debruyne JC, Versijpt J, Van Laere KJ et al (2003) PET visualization of microglia in multiple sclerosis patients using [11C]PK11195. Eur J Neurol 10:257–264
58. Debruyne JC, Van Laere KJ, Versijpt J et al (2002) Semiquantification of the peripheral-type benzodiazepine ligand [11C]PK11195 in normal human brain and application in multiple sclerosis patients. Acta Neurol Belg 102:127–135
59. Versijpt J, Debruyne JC, Van Laere KJ et al (2005) Microglial imaging with positron emission tomography and atrophy measurements with magnetic resonance imaging in multiple sclerosis: a correlative study. Mult Scler 11:127–134
60. Ratchford JN, Endres CJ, Hammoud DA et al (2011) Decreased microglial activation in MS patients treated with glatiramer acetate. J Neurol 259:1199–1205. doi:10.1007/s00415-011-6337-x
61. Giannetti P, Politis M, Su P et al (2015) Increased PK11195-PET binding in normal-appearing white matter in clinically isolated syndrome. Brain 138:110–119. doi:10.1093/brain/awu331
62. Oh U, Fujita M, Ikonomidou VN et al (2011) Translocator protein PET imaging for glial activation in multiple sclerosis. J Neuroimmune Pharmacol 6:354–361. doi:10.1007/s11481-010-9243-6
63. Takano A, Piehl F, Hillert J et al (2013) In vivo TSPO imaging in patients with multiple sclerosis: a brain PET study with [18F]FEDAA1106. EJNMMI Res 3:30. doi:10.1186/2191-219X-3-30
64. Vas A, Shchukin Y, Karrenbauer VD et al (2008) Functional neuroimaging in multiple sclerosis with radiolabelled glia markers: preliminary comparative PET studies with [11C]vinpocetine and [11C]PK11195 in patients. J Neurol Sci 264:9–17. doi:10.1016/j.jns.2007.07.018
65. Park E, Gallezot JD, Delgadillo A et al (2015) (11)C-PBR28 imaging in multiple sclerosis patients and healthy controls: test–retest reproducibility and focal visualization of active white matter areas. Eur J Nucl Med Mol Imaging 42:1081–1092. doi:10.1007/s00259-015-3043-4
66. Collste K, Forsberg A, Varrone A et al (2015) Test-retest reproducibility of [C]PBR28 binding to TSPO in healthy control subjects. Eur J Nucl Med Mol Imaging. doi:10.1007/s00259-015-3149-8
67. Colasanti A, Guo Q, Muhlert N et al (2014) In vivo assessment of brain white matter inflammation in multiple sclerosis with 18F-PBR111 PET. J Nucl Med 55:1112–1118. doi:10.2967/jnumed.113.135129
68. Skoog B, Tedeholm H, Runmarker B, Oden A, Andersen O (2014) Continuous prediction of secondary progression in the individual course of multiple sclerosis. Mult Scler Relat Disord 3:584–592. doi:10.1016/j.msard.2014.04.004
69. Gajofatto A, Calabrese M, Benedetti MD, Monaco S (2013) Clinical, MRI, and CSF markers of disability progression in multiple sclerosis. Dis Mark 35:687–699. doi:10.1155/2013/484959
70. Rizzo G, Veronese M, Tonietto M, Zanotti-Fregonara P, Turkheimer FE, Bertoldo A (2014) Kinetic modeling without accounting for the vascular component impairs the quantification of [(11)C]PBR28 brain PET data. J Cereb Blood Flow Metab 34:1060–1069. doi:10.1038/jcbfm.2014.55
71. Airas L, Dickens A, Elo P et al (2015) In vivo positron emission tomography imaging demonstrates diminished microglial activation after fingolimod treatment in an animal model of multiple sclerosis. J Nucl Med 56:305–310. doi:10.2967/jnumed.114.149955
72. Blackburn MR, Vance CO, Morschl E, Wilson CN (2009) Adenosine receptors and inflammation. Handb Exp Pharmacol. doi:10.1007/978-3-540-89615-9_8
73. Ohta A, Sitkovsky M (2001) Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 414:916–920. doi:10.1038/414916a
74. Garcia GE, Truong LD, Li P, Zhang P, Du J, Chen JF, Feng L (2008) Adenosine A2A receptor activation and macrophage-mediated experimental glomerulonephritis. FASEB J 22:445–454. doi:10.1096/fj.07-8430com
75. Moreau JL, Huber G (1999) Central adenosine A(2A) receptors: an overview. Brain Res Brain Res Rev 31:65–82
76. Rissanen E, Virta JR, Paavilainen T et al (2013) Adenosine A2A receptors in secondary progressive multiple sclerosis: a [(11)C]TMSX brain PET study. J Cereb Blood Flow Metab 33:1394–1401. doi:10.1038/jcbfm.2013.85
77. Masuch A, Shieh CH, van Rooijen N, van Calker D, Biber K (2015) Mechanism of microglia neuroprotection: involvement of P2X7, TNFalpha, and valproic acid. Glia. doi:10.1002/glia.22904
78. Rudolph DA, Alcazar J, Ameriks MK et al (2015) Novel methyl substituted 1-(5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanones are P2X7 antagonists. Bioorg Med Chem Lett 25:3157–3163. doi:10.1016/j.bmcl.2015.06.004
79. Janssen B, Vugts DJ, Funke U et al (2014) Synthesis and initial preclinical evaluation of the P2X7 receptor antagonist [(1)(1)C]A-740003 as a novel tracer of neuroinflammation. J Labelled Compd Radiopharm 57:509–516. doi:10.1002/jlcr.3206
80. Stella N (2010) Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia 58:1017–1030. doi:10.1002/glia.20983
81. Saccomanni G, Pascali G, Carlo SD et al (2015) Design, synthesis and preliminary evaluation of (18)F-labelled 1,8-naphthyridin- and quinolin-2-one-3-carboxamide derivatives for PET imaging of CB2 cannabinoid receptor. Bioorg Med Chem Lett 25:2532–2535. doi:10.1016/j.bmcl.2015.04.055
82. Savonenko AV, Melnikova T, Wang Y et al (2015) Cannabinoid CB2 receptors in a mouse model of abeta amyloidosis: immunohistochemical analysis and suitability as a PET biomarker of neuroinflammation. PLoS ONE 10:e0129618. doi:10.1371/journal.pone.0129618
83. Slavik R, Grether U, Muller Herde A et al (2015) Discovery of a high affinity and selective pyridine analog as a potential positron emission tomography imaging agent for cannabinoid type 2 receptor. J Med Chem 58:4266–4277. doi:10.1021/acs.jmedchem.5b00283
84. Yrjola S, Sarparanta M, Airaksinen AJ et al (2015) Synthesis, in vitro and in vivo evaluation of 1,3,5-triazines as cannabinoid CB2 receptor agonists. Eur J Pharm Sci 67:85–96. doi:10.1016/j.ejps.2014.11.003
85. Funke U, Vugts DJ, Janssen B et al (2013) (11) C-labeled and (18) F-labeled PET ligands for subtype-specific imaging of histamine receptors in the brain. J Labelled Compd Radiopharm 56:120–129. doi:10.1002/jlcr.3038
86. Schieferstein H, Ross TL (2013) (18) F-labeled folic acid derivatives for imaging of the folate receptor via positron emission tomography. J Labelled Compd Radiopharm 56:432–440. doi:10.1002/jlcr.3104
87. Tietz O, Marshall A, Wuest M, Wang M, Wuest F (2013) Radiotracers for molecular imaging of cyclooxygenase-2 (COX-2) enzyme. Curr Med Chem 20:4350–4369
88. Bakshi R, Thompson AJ, Rocca MA et al (2008) MRI in multiple sclerosis: current status and future prospects. Lancet Neurol 7:615–625. doi:10.1016/S1474-4422(08)70137-6
89. Miki Y, Grossman RI, Udupa JK, Wei L, Polansky M, Mannon LJ, Kolson DL (1999) Relapsing-remitting multiple sclerosis: longitudinal analysis of MR images–lack of correlation between changes in T2 lesion volume and clinical findings. Radiology 213:395–399
90. Nijeholt GJ, van Walderveen MA, Castelijns JA et al (1998) Brain and spinal cord abnormalities in multiple sclerosis. Correlation between MRI parameters, clinical subtypes and symptoms. Brain 121(Pt 4):687–697
91. Studholme C, Hill DL, Hawkes DJ (1997) Automated three-dimensional registration of magnetic resonance and positron emission tomography brain images by multiresolution optimization of voxel similarity measures. Med Phys 24:25–35
92. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL (1996) Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 16:834–840. doi:10.1097/00004647-199609000-00008
93. Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ (1997) Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage 6:279–287. doi:10.1006/nimg.1997.0303
94. Gunn RN, Lammertsma AA, Cunningham VJ (1998) Parametric imaging of ligand-receptor interactions using a reference tissue model and cluster analysis. In: Carson RE, Daube-Witherspoon ME, Herscovitch P (eds) Quantitative functional brain imaging with positron emission tomography. Academic Press, San Diego, pp 401–406
95. Ashburner J (2007) A fast diffeomorphic image registration algorithm. Neuroimage 38:95–113. doi:10.1016/j.neuroimage.2007.07.007
96. Heckemann RA, Keihaninejad S, Aljabar P, Rueckert D, Hajnal JV, Hammers A (2010) Improving intersubject image registration using tissue-class information benefits robustness and accuracy of multi-atlas based anatomical segmentation. Neuroimage 51:221–227. doi:10.1016/j.neuroimage.2010.01.072
97. Rueckert D, Sonoda LI, Hayes C, Hill DL, Leach MO, Hawkes DJ (1999) Nonrigid registration using free-form deformations: application to breast MR images. IEEE Trans Med Imaging 18:712–721. doi:10.1109/42.796284
98. Schmidt P, Gaser C, Arsic M et al (2012) An automated tool for detection of FLAIR-hyperintense white-matter lesions in multiple sclerosis. Neuroimage 59:3774–3783. doi:10.1016/j.neuroimage.2011.11.032
99. Varga J, Szabo Z (2002) Modified regression model for the Logan plot. J Cereb Blood Flow Metab 22:240–244. doi:10.1097/00004647-200202000-00012